Merck MRK
-
Merck & Co., Inc. Management Presents at UBS Global Healthcare Conference (Transcript)
Merck & Co., Inc. ( MRK ) UBS Global Healthcare Conference Call ..... pharma for UBS. And it's great to have Merck here. We have Peter Kellogg, who is ..... seekingalpha.com/article/1447881- merck -amp-co-inc-management-presents-at-ubs-global-healthcare-conference-transcript …
-
UPDATE 3-FDA staff says Merck's sleep drug effective, questions dosage
… Cite risk of next-day sedation, suicidal thinking * Merck shares fall 1 percent in midday trading By Toni Clarke WASHINGTON, May 20 (Reuters) - Merck & Co's experimental insomnia drug suvorexant appears generally …
-
FDA staff say Merck's sleep drug effective, question dose levels
May 20 (Reuters) - *FDA STAFF REVIEWERS SAY CLINICAL TRIALS OF MERCK 'S SLEEP DRUG SUVOREXANT "OVERALL, ESTABLISH EFFECTIVENESS." *FDA STAFF REVIEWERS SAY SUVOREXANT SEEMS TO BE ASSOCIATED WITH …
-
Oncothyreon A Speculative Buy
By Northwest Trader: On December 19th, 2012 Oncothyreon's ( ONTY ) shares fell roughly 50% as development partner Merck KGaA ( MKGAY.PK ) reported that L-BLP25 (or Stimuvax), a cancer immunotherapy that was being tested against non small-cell …
-
Oncothyreon ([[ONTY]] +0.9%) gets a boost from Wedbush today, as the firm upgrades he stock to Outperform and raises the price target from $2 to $5. Wedbush says that its partner Merck KgA may be ...
… price target from $2 to $5. Wedbush says that its partner Merck KgA may be successful in negotiating a path to approval ..... and anticipated new data from ongoing clinical trials. Merck expects to provide an update on their discussion with regulators …
-
Bristol-Myers, Merck And Roche: R&D Finds Golden Pill, So Buy
… Cancer Drugs' New Weapon ." Based on "immunotherapy," each of the R&D departments at Bristol-Myers ( BMY ), Merck ( MRK ) and Roche ( RHHBF.PK ) are creating new cancer-fighting drugs. What makes the news exciting is that the drugs …
-
Oncothyreon ([[ONTY]] -20.7%) tanks today after presenting data as ASCO that showed Phase III trials of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 didn't meet its primary ...
… antigen-specific cancer immunotherapy L-BLP25 didn't meet its primary objective . The trial was conducted by Merck Serono, a division of Merck ( MRK -0.7% ), under a license agreement with ONTY . Post your comment!
-
Can Merck's Pipeline Offset The Pain From Major Patent Expirations?
By Trefis : The pressure on Merck 's ( MRK ) revenue growth is likely to continue ..... moderate in the latter half of 2013. Merck 's best bet lies in its R&D to ..... In this analysis, we'll look at Merck 's problems and what the company …
-
Merck's Management Discusses Q1 2013 Results - Earnings Call Transcript
Merck KGaA ( MKGAF.PK ) Q1 2013 Results Earnings ..... Dear ladies and gentlemen, welcome to the Merck Analyst Call on the First Quarter Results ..... seekingalpha.com/article/1434411- merck -s-management-discusses-q1-2013-results-earnings-call-transcript …
-
Merck KGaA Reports In Line 1Q, Rebif Continues to Benefit from Price Increases
Merck KGaA MKGAY reported first-quarter results ..... traditionally one of the year's lightest for Merck , but this year is unlikely to follow that ..... the back half of the year. In addition, Merck is going to see increased competition from …